Lux Health Tech Acquisition Corp.
Cash in trust
$346M
$345,533,790
Trust per share
$10.02
Redemption value
IPO
Oct 2020
$345M raised
Combination deadline
—
Not disclosed
Filings on record
63
Latest Jan 19, 2023
Overview
Lux Health Tech Acquisition Corp. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001823767. It completed its initial public offering in Oct 2020, raising $345M in gross proceeds. The vehicle is sponsored by Lux Encore through Lux Encore Sponsor, LP. The mandate targets technology, healthcare. Deadline lapsed without a deal; trust returned to public shareholders.
“We intend to focus our search for a target business at the intersection of the healthcare and technology industries.”
Reading the filings
Arithmetic on what Lux Health Tech Acquisition Corp. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.
Trust versus the $10 unit
The trust holds $10.02 per public share, 0.2% above the $10.00 the units were sold at. That spread is accrued interest on the trust and, where the charter provides for it, sponsor contributions paid in to buy more time. It is the floor a public shareholder can redeem at, not a valuation of the business.
Sponsor promote
The sponsor's founder block is 8,625,000 shares against 34,500,000 public shares, or 20.0% of the combined count, acquired before the IPO at nominal cost. That promote is the structural dilution every public shareholder carries into a combination, and it is why the economics of a de-SPAC differ so sharply from a conventional IPO.
Warrant coverage
Each unit carried one-third warrant per unit. Warrants are dilution deferred: they cost the holder nothing until exercised, and they overhang the post-combination share count. Thinner coverage is generally a sign of a stronger book at pricing.
Underwriting
Credit Suisse led the offering. It has been named on 118 SPAC IPOs, book-running 92 of them, and 58.3% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.
Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.
63 filings in all. 2 in the last three months, against a busiest month of 19.
News on Lux Health Tech Acquisition Corp.
Last 90 daysNothing in the last 90 days that names this vehicle. We attribute a story only when the release carries the ticker or the registered name, so an empty section means no press release or wire story matched — not that nothing was published. The filings below are the primary record either way.
SEC filing history
Free tier: filings older than 24 hours- SC 13G/A
SC 13G/A
Accession 0001193125-23-010619
- 15-12G
Deregistration of securities
Accession 0000950123-22-011116
- 25-NSE
Notification of delisting
Accession 0001354457-22-000609
- 8-K
Regulation FD disclosure
Items 7.01, 9.01 · Accession 0001564590-22-033801
- DEF 14A
Definitive proxy statement
Accession 0001564590-22-032009
- PRER14A
PRER14A
Accession 0001564590-22-031902
- PRE 14A
PRE 14A
Accession 0001564590-22-031207
- 8-K
Regulation FD disclosure
Items 7.01, 9.01 · Accession 0001564590-22-031029
- UPLOAD
SEC staff comment letter
Accession 0000000000-22-009538
- CORRESP
Correspondence with SEC staff
Accession 0001564590-22-030665
- 10-Q
Quarterly report
Accession 0001564590-22-029298
- UPLOAD
SEC staff comment letter
Accession 0000000000-22-008605
- 8-K
Entry into a material definitive agreement
Items 1.01, 2.03, 9.01 · Accession 0001564590-22-026288
- SC 13G
Beneficial ownership report (passive)
Accession 0001193125-22-157628
- 10-Q
Quarterly report
Accession 0001564590-22-020108
- 10-K
Annual report
Accession 0001564590-22-012588
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0000902664-22-001639
- SC 13G
Beneficial ownership report (passive)
Accession 0001357550-22-000084
- SC 13G/A
Amended beneficial ownership report (passive)
Accession 0001319244-22-000084
- 10-K/A
10-K/A
Accession 0001564590-22-001347
- 8-K
Entry into a material definitive agreement
Items 1.01, 2.03, 9.01 · Accession 0001564590-21-059291
- 8-K
Current report
Item 4.02 · Accession 0001564590-21-057269
- 10-Q
Quarterly report
Accession 0001564590-21-057262
- NT 10-Q
Late quarterly report notification
Accession 0001564590-21-057128
- 10-Q
Quarterly report
Accession 0001564590-21-044235
- 10-Q
Quarterly report
Accession 0001564590-21-035136
- 10-K/A
10-K/A
Accession 0001564590-21-032007
- SC 13G/A
SCHEDULE 13G (AMENDMENT NO. 2)
Accession 0000899140-21-000521
- 8-K
Notice of delisting or failure to satisfy a listing rule; Other events
Items 3.01, 8.01, 9.01 · Accession 0001564590-21-030818
- 8-K
Current report
Item 4.02 · Accession 0001564590-21-028691
Pro
Track Lux Health Tech Acquisition Corp. without the delay
Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.
- Filings live, no 24-hour delay
- One click through to the source document
- Deadline calendar out to 12 months
- CSV export, API and MCP access
Cancel any time. Billed monthly in USD.
Lux Health Tech Acquisition Corp.: questions answered
What is Lux Health Tech Acquisition Corp.?
Lux Health Tech Acquisition Corp. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001823767. It completed its initial public offering in Oct 2020, raising $345M in gross proceeds. The vehicle is sponsored by Lux Encore through Lux Encore Sponsor, LP. The mandate targets technology, healthcare. Deadline lapsed without a deal; trust returned to public shareholders.
How much does Lux Health Tech Acquisition Corp. hold in trust?
Approximately $345,533,790, or about $10.02 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.
When must Lux Health Tech Acquisition Corp. complete a merger?
No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.
What happens if Lux Health Tech Acquisition Corp. does not find a target in time?
The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.
Can I redeem shares in Lux Health Tech Acquisition Corp., and at what price?
Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $10.02 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.
Is the trust value the same as the share price for Lux Health Tech Acquisition Corp.?
No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.
How much dilution do Lux Health Tech Acquisition Corp.'s founder shares and warrants create?
The founder block is 8,625,000 shares against 34,500,000 public shares, so roughly 20.0% of the combined count sits with the sponsor at nominal cost. Each unit also carried one-third warrant per unit, which is dilution deferred until exercise. Both are disclosed in the prospectus and both survive into the combined company, which is why a de-SPAC at $10 is not economically the same as an IPO at $10.
Who sponsors Lux Health Tech Acquisition Corp., and what is their track record?
Lux Encore Sponsor, LP is the sponsor entity, part of the Lux Encore franchise. This is the only vehicle we have attributed to that sponsor. Named principals: Josh DeFonzo.
Which banks underwrote the Lux Health Tech Acquisition Corp. IPO?
Credit Suisse, Stifel. Credit Suisse and Stifel were credited as book-running managers on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.
Is Lux Health Tech Acquisition Corp. a good investment?
That is not a question this site answers. Lux Health Tech Acquisition Corp. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.
Where does this Lux Health Tech Acquisition Corp. data come from?
Filings Lux Health Tech Acquisition Corp. submitted to the SEC under CIK 0001823767: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.
Compiled by the SPACListing research desk
Last reconciled Oct 19, 2026
Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.
Read the full methodology · What is in the dataset · Report a correction
SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.
Continue reading
The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.
Lux Encore: the full record
Every vehicle this sponsor has launched, what closed, what liquidated and what is still live.
Credit Suisse in SPACs
Mandates, bookrun credit, deal volume and the outcome of the vehicles it priced.
Technology SPACs
Every vehicle chasing the same mandate, ranked by cash in trust.
All liquidated spacs
Deadline lapsed without a deal; trust returned to public shareholders.
Deadline calendar
Which sponsors are running out of time, and when the extension votes land.
What is a SPAC?
The structure, the economics and where the risks actually sit.
SPAC glossary
Every term in a blank-check filing, defined the way practitioners use it.
How this data is built
Coverage universe, ingestion, normalisation, lifecycle classification and known limits.